Institut Jules Bordet
Institut Jules Bordet – A Leading Comprehensive Cancer Center in Europe
The Institut Jules Bordet is an internationally recognized comprehensive cancer center, dedicated entirely to cancer care, research, and education. As part of the Hôpital Universitaire de Bruxelles (HUB), alongside the Erasme Hospital and the Queen Fabiola Children’s University Hospital, we combine expertise, innovation, and multidisciplinary excellence to advance oncology in Belgium and beyond.
For over 80 years, the Institut Jules Bordet has been at the forefront of cutting-edge cancer treatment and research, offering personalized, patient-centered care. Our internationally renowned specialists work across disciplines to develop innovative therapies and participate in leading clinical trials to improve patient outcomes.
With the recent move to our state-of-the-art facilities within HUB, we have expanded our capacity to provide world-class cancer care, ensuring access to the latest technological advancements and therapeutic approaches. Through active participation in European research projects like Path-For-Young, we continue to drive progress in oncology and contribute to the future of cancer treatment.
At the Institut Jules Bordet, our mission is clear: to defeat cancer through innovation, collaboration, and excellence in patient care.
Role
Within the Path-For-Young project, Institut Jules Bordet (IJB) plays a central role in Prosigna testing, overseeing its implementation, execution, and quality control. JB ensures standardized procedures across testing laboratories, coordinates sample processing, and monitors testing workflows to optimize efficiency. Additionally, IJB actively contributes to patient-centered research by analyzing treatment-related burdens, risk perception, and long-term outcomes. Through its expertise in molecular diagnostics and clinical research, JB strengthens the project's scientific rigor, ensuring high-quality data and improved patient care strategies.
Members
Christos Sotiriou
Dr. Sotiriou is currently the Research Director at the “Fonds de la Recherche Scientifique” (FNRS), a “chef de Clinique” at the Jules Bordet Institute, and was recently appointed as Director of the Bordet Cancer Research Laboratories of the Jules Bordet Institute. His primary research focuses on improving the molecular understanding of breast cancer biology, disease dissemination, and progression by using state-of-the-art omics technologies and developing prognostic and predictive biomarkers for breast cancer. With an H-index of more than 100 and over 300 publications in high-impact journals, Dr. Sotiriou is a widely recognized thought leader. He is an active member of numerous scientific and abstract review committees, such as the AACR, SABCS, ASCO, and the ESMO conferences. He is the Associate Editor for breast cancer for Annals of Oncology, ESMO’s official journal. He is an Advisory Council Member of Susan G. Komen for the Cure® and a former elected member of the Scientific Council of the International Agency for Research on Cancer for Belgium (IARC- WHO, 2012 to 2016). He is an editorial board member for the WHO Classification of Breast Tumors (4th, 5th and 6th WHO Blue Books, breast cancer edition). He is a fellow of the European Academy of Cancer Sciences, and since 2022, he has become a member of the Académie Royale de Médecine de Belgique. Dr. Sotiriou has received many prestigious awards, including the 2015 “Joseph Maisin Scientific Prize - Clinical Biomedical Sciences,” a quinquennial prize awarded by the F.R.S. FNRS. Over the past 20 years, he has succeeded in obtaining steady, independent, peer-reviewed research funding.
Françoise Rothé
Françoise Rothé was appointed Associate Professor at the Faculty of Medicine from the Université Libre de Bruxelles in 2020. She is also associate director of the Bordet Cancer Research Laboratories of the Jules Bordet Institute. Her main research focus is to improve the molecular understanding of the biology, dissemination and progression of breast cancer using state-of-the-art technologies. In particular, the aim is to interrogate the molecular heterogeneity of breast cancer and its microenvironment, with the ultimate goal being to improve breast cancer care. Being molecular biologist by training, she is also responsible of the technical development in the lab and recently implemented spatial transcriptomics and single cell analysis platforms allowing an in depth characterization of tumor and stroma cell composition and organization. She has 59 peer-reviewed publications in high-impact journals and an H-score of 36.